A molecular test for the herpes simplex virus, known as the MultiCode-RTx HSV 1&2 kit, developed by EraGen Biosciences, has received 510(k) clearance from the US Food and Drug Administration (FDA).

The HSV 1&2 kit is used for the detection and typing of the virus in symptomatic women, and uses patented MultiCode-RTx technology based on the company’s synthetic DNA base pair: isoC:isoG test.

The kit is an alternative in HSV testing that can differentiate between HSV-1 and HSV-2 in vaginal lesion specimens from symptomatic female patients.

It provides rapid time to result, streamlined workflow and simple implementation for both large and small laboratories.